...In November, Synergy said it expects 2018 Trulance sales of $42-$47 million. Bausch also gains dolcanatide...
...NASDAQ:SGYP), New York, N.Y. Bausch Health Companies Inc. (TSX:BHC; NYSE:BHC), Laval, Quebec Business: Gastrointestinal Shannon Lehnbeuter Dolcanatide (SP-333) Trulance...

...for chronic, non-cancer pain for =3 months showed that once-daily 3 and 6 mg oral SP-333...
...increase of 1.8 SBMs, p=0.009 and p=0.005). Additionally, the 3 and 6 mg doses of SP-333...
...for the 1 mg dose of SP-333. Synergy Pharmaceuticals Inc. (NASDAQ:SGYP), New York, N.Y. Product: SP-333...

...in a double-blind, placebo-controlled Phase II trial to evaluate 1, 3 and 6 mg oral SP-333...
...per week and who experience constipation-related symptoms. Synergy Pharmaceuticals Inc. (NASDAQ:SGYP), New York, N.Y. Product: SP-333...

...began a double-blind, placebo-controlled Phase II trial to evaluate 1, 3 and 6 mg oral SP-333...
...per week and who experience constipation-related symptoms. Synergy Pharmaceuticals Inc. (NASDAQ:SGYP), New York, N.Y. Product: SP-333...

...This quarter, Synergy will start a dose-ranging Phase II trial to evaluate once-daily oral SP-333 for...
...for chronic, non-cancer pain for >=3 months. Synergy Pharmaceuticals Inc. (NASDAQ:SGYP), New York, N.Y. Product: SP-333...

...doses of SP-333 in 64 healthy adults. Synergy Pharmaceuticals Inc. (NASDAQ:SGYP), New York, N.Y. Product: SP-333...

...dose-escalation, U.S. Phase I trial in about 56 healthy volunteers showed that single doses of SP-333...
...Phase I trial of SP-333 this month. Synergy Pharmaceuticals Inc. (NASDAQ:SGYP), New York, N.Y. Product: SP-333...

...to evaluate single ascending-doses of 0.1, 0.3, 1, 3, 10, 30 and 60 mg oral SP-333...
...I trial is slated for early 2013. Synergy Pharmaceuticals Inc. (NASDAQ:SGYP), New York, N.Y. Product: SP-333...

...IIb/III testing to treat chronic idiopathic constipation (CIC), with data expected by year end; and SP-333...